What I Tell My Patients About...

Genetic Testing in Newly Diagnosed Advanced Ovarian Cancer (OC)

• Frequency and clinical significance of germline and somatic BRCA mutations in OC
• Incidence and clinical relevance of other inherited or somatic mutations (eg, RAD51C, RAD51D, ATM)
• Definition of homologous recombination deficiency (HRD); rationale for determining HRD status in patients with OC
• Similarities and differences among available genetic testing platforms; role of extended panel testing and next-generation sequencing

Utility of Genetic Counseling After a Diagnosis of OC

• Complementary role of genetic counselors in providing information about the significance of inherited germline versus somatic mutations to patients with OC
• Implications for immediate family when an inherited mutation has been identified
• Communication with patients’ families regarding the potential benefits of genetic testing
• Common access barriers to genetic counseling services and means to overcome them

Role of PARP Inhibitor Maintenance Therapy in Newly Diagnosed Advanced OC

• Mechanism of antitumor activity of PARP inhibitors; similarities and differences among olaparib, niraparib and rucaparib
• Rationale for PARP inhibitors as maintenance therapy for patients with OC
• Long-term efficacy and safety findings from Phase III studies supporting the use of maintenance olaparib, niraparib and olaparib/bevacizumab for patients with newly diagnosed OC
• Clinical, biologic and practical factors in the selection of olaparib, niraparib or olaparib/bevacizumab for maintenance therapy
• Other promising PARP inhibitor-based strategies under investigation in the first-line maintenance setting (eg, niraparib/bevacizumab, rucaparib)

Selection and Sequencing of Therapy for Relapsed OC

• Defining “platinum sensitive” and “platinum resistant” for patients with relapsed OC; implications for prognosis and later-line treatment selection
• Pivotal clinical trial findings with niraparib, olaparib and rucaparib for platinum-sensitive and platinum-resistant recurrent OC
• Patient- and disease-related factors in the selection of a PARP inhibitor in the relapsed setting
• Recently presented data documenting the utility of rechallenge with a PARP inhibitor for patients who have experienced disease progression on or after PARP inhibitor therapy; current role in clinical practice
• Prevalence of BRCA reversion mutations among patients with relapsed OC and ramifications for selection of later-line treatment

Tolerability of PARP Inhibitors Used in the Treatment of OC

• Incidence, timing and severity of common class- and agent-specific toxicities associated with PARP inhibitors in patients with OC
• Risk of long-term, serious side effects with PARP inhibitor therapy, such as acute myeloid leukemia and myelodysplastic syndromes
• Optimal monitoring and management paradigm for PARP inhibitor-related toxicities
• Role of switching to a different PARP inhibitor for patients who are experiencing tolerability issues

Other Practical Considerations with the Use of PARP Inhibitors for OC

• Initial dosing of approved PARP inhibitors and appropriate dose-modification strategies
• Optimal duration of PARP inhibitors in the maintenance setting
• Strategies to encourage adherence among patients receiving long-term oral medications, including PARP inhibitors
• Documented interaction between approved PARP inhibitors and other prescription drugs and over-the-counter medications and supplements

Potential Benefits of Clinical Trial Participation

• Appropriate identification of patients with OC who may be candidates for clinical trial participation
• Educating patients about the potential advantages of participating in a clinical research study
• Strategies to overcome common patient misperceptions about trial participation (eg, concerns over safety, expense, receiving a placebo, ability to withdraw)
• Preparing interested patients with OC for clinical trial participation; instructions regarding adherence, monitoring requirements, adverse-event reporting, et cetera

Promising Investigational Strategies for Advanced OC

• Biologic rationale for, available data with and ongoing Phase III studies of PARP inhibitors in combination with anti-PD-1/PD-L1 antibodies for OC
• Scientific rationale for targeting folate receptor alpha in advanced OC; available data with and ongoing evaluation of mirvetuximab soravtansine for platinum-resistant disease
• Mechanism of action of tumor treating fields (TTFs); available efficacy and safety data with TTFs in combination with chemotherapy for advanced OC
• Other promising novel agents and strategies under investigation

Thank you for your interest in our NCPD program taking place in Anaheim, CA. At this time online preregistration for in-person is closed for this event. SEATS ARE STILL AVAILABLE FOR THE SESSION. Our Onsite Registration Desk will be open at 11:45 AM Pacific Time on Thursday, April 28th. If you are interested in attending, please visit our registration desk located outside the Grand Ballroom E-K (Lobby Level) of the Anaheim Marriott hotel (700 West Convention Way) which is within walking distance (0.2 miles) of the Anaheim Convention Center.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

Please note, onsite registration does not guarantee meal service which will be based on availability.